Lobby

Introduction and Welcome Remarks

Outsmarting the Escape Artist: Resistance in CAR T-Cell Therapy for Cancers

Developing bespoke gene editing treatments for patients with carbamoyl phosphate synthetase 1 (CPS1) deficiency

Defining the mechanisms that regulate H2BE incorporation and genomic localization

Developing an Aβ-targeting Syn-Notch receptor for delivering payloads in Alzheimer’s disease mouse models

Novel vaccination approaches against HIV-1

Faculty will be assigned tables to lead discussions over lunch. Students may choose any available seat. Posters also on view.

Precise control of HIV proviral transcription using targeted mRNA gene therapy

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence

CLN3 disease disrupts very early postnatal brain maturation

Understanding the impact of PEG lipid on mRNA-LNP vaccine immunogenicity

Multiplexed Synthetic Immunology: Scaling the design and measurement of engineered immune cells for new biological insights and therapies

Lobby

Corrective editing to treat pseudoxanthoma elasticum

Development of a Virus-like Particle mRNA Vaccine against Pneumoviruses

Delivery of a complement modulated, broadly reactive monoclonal antibody targeting the pneumococcal histidine triad protein D (PhtD) improves potency and protection during lethal Streptococcus pneumoniae infectionA

Richard W. Vague Professor in Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy

CAR T Cells: past, present and future

Lobby